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Abstract
Recent studies suggest that FTO variants strongly correlate with obesity and mainly influence energy intake with little effect
on the basal metabolic rate. We suggest that FTO influences eating behavior by modulating intracellular energy levels and
downstream signaling mechanisms which control energy intake and metabolism. Since FTO plays a particularly important
role in adipocytes and in hypothalamic neurons, SH-SY5Y neuronal cells and 3T3-L1 adipocytes were used to understand
how siRNA mediated knockdown of FTO expression alters cellular energy homeostasis. Cellular energy status was evaluated
by measuring ATP levels using a luminescence assay and uptake of fluorescent glucose. FTO siRNA in SH-SY5Y cells
mediated mRNA knockdown (282%), increased ATP concentrations by up to 46% (P=0.013) compared to controls, and
decreased phosphorylation of AMPk and Akt in SH-SY5Y by 252% and 246% respectively as seen by immunoblotting. In
contrast, FTO siRNA in 3T3-L1 cells decreased ATP concentration by 293% (p,0.0005), and increased AMPk and Akt
phosphorylation by 204% and 70%, respectively suggesting that FTO mediates control of energy levels in a cell-type specific
manner. Furthermore, glucose uptake was decreased in both SH-SY5Y (251% p=0.015) and 3T3-L1 cells (230%,
p=0.0002). We also show that FTO knockdown decreases NPY mRNA expression in SH-SY5Y cells (221%) through
upregulation of pSTAT3 (118%). These results provide important evidence that FTO-variant linked obesity may be associated
with altered metabolic functions through activation of downstream metabolic mediators including AMPk.
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Introduction
The Fat Mass and Obesity Associated gene (FTO) associates
with body mass index (BMI), waist circumference, type II
diabetes, and other obesity related traits [1] in individuals that
are homozygous for the FTO risk allele [2], 16% in most world-
wide populations, establishing itself as the focus of intense
research. Substantial evidence suggests that the primary physio-
logical effect of variations in the FTO locus in humans is increased
dietary intake without significant effects on physical activity or
metabolic rates [3,4]. Murine studies of FTO function demon-
strate FTO’s strong influence over energy intake but are
complicated by metabolic disturbances including alterations in
basal metabolic rate and overall energy expenditure not apparent
in human studies [4,5,6,7]. Consequently, current studies have not
determined a potential mechanism which results in increased
energy intake associated with FTO gene variants in humans.
Tissue-specific gene expression profiling suggests that FTO is
highly expressed in the hypothalamus [8], an area of the brain
strongly linked to eating behavior. FTO is also expressed at a
lower level and maintains functionality in adipose and other tissues
[9,10]. Further studies suggest that FTO functions as both a sensor
of energy status [9,11] and a modulator of metabolic processes
[12], and its cellular function may be cell-type specific, since
fasting increases FTO expression in white adipose tissue [9] and
hypothalamic neurons [11] but decreases FTO expression in
brown adipose tissue [9].
Intracellular ATP levels affect cellular function and are tightly
controlled through a variety of sensors and signaling pathways
[13]. Additionally, intracellular energy status regulated by AMP
Kinase plays an important role in controlling organismal energy
intake and energy metabolism by hypothalamic neurons [14].
AMPk (59-Adenosine Monophosphate Activated Protein Kinase)
appears to be the primary sensor of intracellular ATP levels in the
hypothalamus, as it is phosphorylated in the presence of increased
AMP/ATP ratio by the tyrosine kinase LKB1 [15], and is
activated by starvation and inhibited by leptin [14]. Further,
hypothalamic AMPk controls neuropeptide expression, thereby
controlling eating behavior [16], and may control adipocyte
function as well [13].
Our results suggest that downregulation of FTO by siRNA in
both neuronal and adipocyte cells in culture causes a cell-type
specific alteration in cellular ATP levels with a corresponding
alteration in AMPk phosphorylation. We thus hypothesize that
if FTO’s metabolic functions control AMPk in the hypothala-
mus, then AMPk may be the primary driver of the systemic
metabolic effects seen in human and murine studies of FTO
function.
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Validation of siRNA-induced Knockdown of FTO Gene
Expression
To confirm appropriate downregulation of FTO in both naı ¨ve
and differentiated cells, qPCR was performed at several time
points after transfection, and one week after induction of
differentiation. Naı ¨ve (undifferentiated) SH-SY5Y cells treated
with siRNA against FTO exhibited a decrease in FTO mRNA
expression by 281.8%, and 269.8% at 48 and 72 hours,
respectively (Fig 1A). 3T3-L1 cells exhibited 280.3% and
265.3% decrease in FTO mRNA at 48 and 72 hours after
transfection, respectively (Fig 1B). Additionally, sustained knock-
down of FTO mRNA was validated after 1 week of differentiation
in both SH-SY5Y (259.3%) and 3T3-L1 cells (259.6%) (Fig 1A
and 1B).
FTO Knockdown Disrupts Cellular Energy Balance in a
Cell-type Specific Manner
The FTO gene is known to play an important role in controlling
energy balance as previous reports show a strong correlation
between FTO expression and organismal energy status, including
fat accumulation and energy intake [5]. However, little is known
about the relationship between FTO expression and cellular
energy balance, and substantial research has shown that
alterations in neuronal cellular energy status can have large
implications on eating behavior [14]. Thus, to determine if FTO
plays a role in maintaining or controlling cellular energy status, we
examined the effect of FTO knockdown on ATP levels in both
Figure 1. Downregulation of FTO mRNA expression in SH-SY5Y cells and its effects on ATP concentration.( A) SH-SY5Y cells were
transfected with siRNA for 24 hours and then incubated for a total of 48 hrs (281.8%) or 72 hrs (269.8%) post-transfection. Additionally, SH-SY5Y
cells were transfected with siRNA for 48 hrs and then differentiated for 1 week (259.3%). GAPD mRNA was used as a positive internal control. (B) 3T3-
L1 cells were transfected as described above and FTO expression was decreased by 280.3% at 48 hrs post-transfection, 65.3% at 72 hrs post-
transfection, and 59.6% after 48 hrs of transfection and 1 week of differentiation. (C, D) FTO knockdown modulates ATP levels in SH-SY5Y and 3T3-L1
cells. Cells were transfected with siRNA and then incubated for 48 hrs post-transfection or differentiated for 1 week. (C) ATP levels were increased in
naı ¨ve SH-SY5Y cells treated with glucose free DMEM only (46%, p=0.013), oligomycin (30%, p,0.0001), and differentiated SH-SY5Y cells treated with
only glucose-free DMEM (16% p=0.05), but decreased in differentiated SH-SY5Y cells treated with oligomycin (216%, p=0.19). (D) ATP levels were
decreased in naı ¨ve 3T3-L1 cells treated with glucose free DMEM only (293%, p=0.0005), oligomycin (276%, p=0.00002), and differentiated 3T3-L1
cells treated with only glucose-free DMEM (254% p=0.0068), yet increased in differentiated 3T3-L1 cells treated with oligomycin (179%, p=0.026).
Values indicate percent of control. ATP results are average of 2 independent experiments performed in at least quadruplicate and analyzed by one-
way ANOVA with post-hoc analysis with a at 0.05. (E, F) FTO knockdown does alter cell viability of SH-SY5Y and 3T3-L1 cells. Cells were transfected
with siRNA, incubated for 48 hrs and viable cells were collected and counted. (E) No difference was found between FTO siRNA treated SH-SY5Y cells
and Control siRNA treated cells (p=0.35). In addition, no difference in the cell viability was detected in FTO siRNA treated SH-SY5Y cells after exposure
to oligomycin (p=0.77). (F) There is no difference in FTO siRNA or Control siRNA treated 3T3-L1 cells (p=0.35) or in Control siRNA treated 3T3-L1 cells
treated with oligomycin compared to FTO siRNA treated cells (p=0.131). Cell viability results are the result of experiments performed in
quadruplicate and analyzed by repeated measures ANOVA with a at 0.05.
doi:10.1371/journal.pone.0038444.g001
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ATP levels after siRNA transfection, naı ¨ve or differentiated cells
were incubated for 30 minutes in glucose-free media, to inhibit
glycolysis, with or without oligoymycin A, a specific inhibitor of
ATP synthase, to completely inhibit the production of new ATP.
In naive SH-SY5Y cells, FTO knockdown increased ATP levels
in cells treated with oligomycin by 46% (FTO siRNA
3746663263 Luminescence units (LU) vs Control siRNA
25624361439 LU; p=0.013; N=6) and in cells treated with
only glucose-free media by 30% (FTO siRNA 1393330642889
LU vs Control siRNA 1073143653304 LU; p,0.0001; N=6)
(Fig 1C). However, in differentiated SH-SY5Y cells, ATP levels
increased marginally in cells treated with glucose-free media (16%,
FTO siRNA 1524949645660 LU vs Control siRNA
12762646117101 LU; p=0.05; N=5) (Fig 1C). Interestingly, in
differentiated SH-SY5Y cells treated with oligomycin, treatment
with FTO siRNA appears to marginally decrease cellular ATP
content (216%, FTO siRNA 746552652886 LU vs Control
siRNA 886431681662 LU; p=0.19; N=5) (Fig 1C). In stark
contrast, naı ¨ve 3T3-L1 cells treated with FTO-siRNA showed a
decrease in ATP concentration by 293% (FTO siRNA 51296738
LU vs Control siRNA 7276866759 LU; p=0.0005; N=5) and
276% (FTO siRNA 515061000 LU vs Control siRNA
2165061359 LU; p=0.00002; N=5) in cells treated with
glucose-free media or oligomycin, respectively (Fig 1D). However,
differentiated 3T3-L1 cells displayed a decrease in ATP levels only
in cells treated with glucose-free media (254%, FTO siRNA
52323610932 LU vs Control siRNA 132734619360 LU;
p=0.0068; N=6), while differentiated 3T3-L1 cells treated with
oligomycin displayed an increase in ATP levels as compared to
controls (179%, FTO siRNA 1248962187 LU vs Control siRNA
44676790 LU; p=0.026; N=4) (Fig 1D). These results suggest
that a decrease in FTO gene expression may alter cellular ATP
levels and provides additional evidence that FTO’s contribution to
obesity is cell-type specific.
Cellular Proliferation is Unaffected by Exposure to FTO
siRNA
To study the effect of FTO siRNA treatment on cellular
proliferation in SH-SY5Y and 3T3-L1 cells, we plated and treated
cells as described below and subsequently trypsinized and counted
viable cells. FTO siRNA did not cause a change in cell viability in
either SH-SY5Y (FTO siRNA 66.661.4 cells/high power field
(hpf) vs Control siRNA 65.262.3 cells/hpf; p=0.35; N=4)
(Fig 1E) or 3T3-L1 cells (FTO siRNA 39.963.6 cells/hpf vs
Control siRNA 40.863.8 cells/hpf; p=0.77; N=4) (Fig 1F).
To confirm that changes in ATP levels in response to FTO
siRNA are not due to differences in cell survival after oligomycin
treatment, FTO siRNA and Control siRNA treated SH-SY5Y and
3T3-L1 cells were exposed to oligomycin for 30 minutes, collected
and counted. Exposure to oligomycin does not alter cell survival in
FTO siRNA treated SH-SY5Y cells (FTO siRNA 67.861.8 cells/
hpf vs Control siRNA 66.260.9 cells/hpf; p=0.35; N=4) (Fig 1E)
or 3T3-L1 cells (FTO siRNA 37.461.4 cells/hpf vs Control
siRNA 32.660.9 cells/hpf; p=0.131; N=4) (Fig 1F) as compared
to Control siRNA treated cells. These results suggest that
alterations in ATP levels in response to FTO knockdown are
not caused by changes in cell viability.
Effect of siRNA Targeting the FTO Gene on Cellular
Signaling and Glucose Uptake
After determining the effect of FTO knockdown on cellular
ATP levels, we wanted to examine additional metabolic traits
modulated by FTO expression. To determine if FTO downreg-
ulation affects glucose uptake in SH-SY5Y neuronal cells and 3T3-
L1 adipocytes, cells were treated with FTO siRNA and glucose
uptake was determined by measuring uptake of fluorescent 2-
NBDG. As shown in Figure 2A, glucose uptake into both naı ¨ve
and differentiated SH-SY5Y cells was significantly decreased by
227% (FTO siRNA 9804067898 (Fluorescence units (FU) vs
Control siRNA 13422064648 FU; p=0.007; N=5) and 251%
(FTO siRNA 6595267281 FU vs Control siRNA 135202617647
FU; p=0.015; N=5), respectively. Additionally, glucose uptake
into naı ¨ve and differentiated 3T3-L1 adipocytes was decreased by
222% (siRNA 3561662501 FU vs Control siRNA 4574563000
FU; p=0.017; N=5) and 230% (siRNA 12276463634 FU vs
Control siRNA 17458163643 FU; p=0.0002; N=5), respectively
(Fig 3A).
To further explore the metabolic consequences of decreased
FTO expression, we immunoblotted for total and phosphorylated
AMPK (Thr
172) (pAMPk) in FTO deficient SH-SY5Y and 3T3-L1
cells. AMPk is an important sensor of cellular energy status [14]
that is phosphorylated in the presence of an elevated AMP/ATP
ratio by the serine/threonine kinase, LKB1 [17]. AMPk controls
multiple cellular metabolic processes including glucose uptake and
fatty acid synthesis and may play a role in hypothalamic energy
sensing and modulation of eating behavior [14]. As seen in
Figure 2B, FTO knockdown decreases AMPk phosphorylation by
251.8% and 252.3% in both naı ¨ve and differentiated SH-SY5Y
cells, respectively, without a significant alteration in total AMPk
levels. However, FTO-deficient 3T3-L1 adipocytes exhibit a
significant increase (204% naı ¨ve, 38% differentiated) in pAMPK
(Thr
172) without a change in total AMPk (Fig 3B). Since FTO-
siRNA does not significantly affect total AMPk protein expression,
it is possible that cell-type specific alteration in ATP levels
following FTO knockdown are responsible for the cell-type specific
alteration in AMPk phosphorylation.
Additionally, Akt, which plays an important role in insulin
stimulated glucose uptake [18], is also modulated by FTO
knockdown. Akt phosphorylation (Ser
473) (pAkt) is decreased in
both naı ¨ve (246%) and differentiated (230%) SH-SY5Y cells,
without a significant change in total Akt levels (Fig 2C). Inversely,
pAkt (Ser
473) is increased in naı ¨ve (70%) and differentiated (25%)
3T3-L1 cells without a significant change in total Akt expression
(Fig 3C).
NPY mRNA Expression is Decreased in FTO-deficient Cells
Currently, energy intake is the only obesity-associated trait
significantly and repeatedly associated with FTO variants
[3,11,19,20,21] in humans. To determine if FTO downregulation
could control the expression of neuropeptides associated with
energy intake, we analyzed the mRNA expression of an orexigenic
neuropeptide, neuropeptide Y (NPY), that encourages energy
intake in the fasted state [22], and an anorexigenic neuropeptide,
Proopiomelanocortin (POMC) [23], that discourages energy
intake after feeding, in both naı ¨ve and differentiated FTO-
deficient SH-SY5Y cells. We observed a significant decrease in
NPY in both naı ¨ve (241%) and differentiated cells (221%)
(Fig 4A), but no change in POMC mRNA in response to FTO
downregulation (data not shown). This corresponds with experi-
ments in mice showing a decrease in NPY expression in FTO
knockout mice [7]. Furthermore, we studied the signal transducer
and activator of transcription 3 (STAT3), an important regulator
of NPY expression [22], that is phosphorylated in the hypothal-
amus by the leptin receptor to inhibit NPY peptide transcription
[22]. In FTO siRNA-treated SH-SY5Y cells, phosphorylated
FTO Knockdown Disrupts Energy Balance
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727) is upregulated 118% in differentiated cells, while
there is no significant change in total STAT3 (Fig 4B).
Discussion
The study presented in this paper attempts to identify the
cellular consequences of FTO downregulation that may account
for the influence of FTO variants on obesity. We show that
downregulation of FTO gene expression by siRNA significantly
modulates cellular concentrations of ATP in both SH-SY5Y
neuronal cells and 3T3-L1 adipocytes in a cell-type specific
manner. We also demonstrate a cell-type specific response in the
phosphorylation of AMPk, an important energy sensor that is
involved in controlling both energy expenditure and intake, in
response to decreased FTO expression. While these results are
preliminary we suggest that our observations may provide the
foundation for a mechanism that links FTO expression and the
development of human obesity.
Presently, it is unclear how FTO expression may contribute to
determining cellular energy status. The FTO gene encodes a 2-
oxoglutarate-dependent nucleic acid-demethylase [24] that may
function as a transcriptional co-activator through CCAAT/
enhancer binding proteins [25]. While previous studies demon-
strate that alterations in energy status including fasting and glucose
administration [8] may influence FTO gene expression [9,11,26],
our study is the first to demonstrate a modulation of cellular
energy status by changes in FTO expression. We propose that
FTO functions as a modulator of cellular energy status exhibited
by alteration in ATP concentrations in response to reduced FTO
expression.
Our data shows an increase in total ATP concentration in both
naive and differentiated FTO-deficient SH-SY5Y cells. In
contrast, FTO deficient 3T3-L1 adipocytes exhibit a significant
decrease in ATP concentration in both naı ¨ve and differentiated
cells (Fig 1). Interestingly, these results are reversed in differenti-
ated SH-SY5Y and 3T3-L1 cells treated with oligomycin A, an
inhibitor of ATP synthase. These results provide substantial
evidence of the involvement of FTO in determining cellular
energy status, and show that FTO may influence energy levels in a
cell-type specific nature. Unfortunately, the mechanism of this
effect is unclear as the observed changes in ATP levels may be
caused by alterations in either production or consumption of ATP.
Abolishing FTO function significantly alters the expression of the
mitochondrial uncoupling protein 2 (Ucp2) [6], and modulation of
FTO expression in human myotubes impacts mitochondrial
oxidative phosphorylation and alters the expression of mitochon-
drial genes including ATP5B, UQCR and SOD2 [26]. These
combined results suggest the presence of a link between FTO
expression and mitochondrial function. However, a link between
Figure 2. Effect of FTO knockdown on glucose uptake and downstream signaling in SH-SY5Y cells.( A) Cells were transfected with siRNA
and then incubated 48 hrs post-transfection or differentiated for 1 week. Cells were then exposed to 80 mM 2-NBDG in DMEM media lacking glucose
and sodium pyruvate for 5 minutes and glucose-associated fluorescence was measured. Glucose uptake was decreased in both naı ¨ve (227%,
p=0.007) and differentiated (251% p=0.015) SH-SY5Y cells. Y-axis represents Arbitrary Fluorescent Units (6SEM) from 2 independent experiments
run in quintuplicate and analyzed by one-way ANOVA with post-hoc analysis. (B) FTO knockdown decreases AMPk activation. SH-SY5Y cells were
transfected with siRNA and then incubated 48 hrs post-transfection or differentiated for 1 week and subsequently immunoblotted. pAMPk (Thr
172)
was decreased in both naı ¨ve (251.8%) and differentiated cells (252.3%) while total AMPk was unchanged. (C) FTO knockdown decreases Akt
phosphorylation. pAkt (Ser
473) was decreased in both naı ¨ve (245.8%) and differentiated cells (230.0%) while total Akt was unchanged. Blots and
densitometry data are from a representative of two similar independent experiments.
doi:10.1371/journal.pone.0038444.g002
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explored.
As seen in Figures 2 and 3, naı ¨ve SH-SY5Y and 3T3-L1 cells
deficient in FTO mRNA display a significant decrease in glucose
uptake (227%, 222%, respectively), with a larger decrease in
glucose uptake occurring in differentiated cells (251%, 230%,
respectively). These results corroborate previous evidence that
FTO expression modulates glucose metabolism [9,12,27]. How-
ever, no study has identified a correlation between glucose uptake
and FTO gene expression and the mechanism of this effect is
unclear. It is possible that the modulation of pAMPk by changes in
ATP levels is responsible for the decrease in glucose uptake seen in
both SH-SY5Y and 3T3-L1 adipocytes. AMPk phosphorylation
decreases glucose uptake in 3T3-L1 adipocytes [28], yet increases
glucose uptake in skeletal muscle, neurons, and other tissues
[28,29]. Thus, we suggest the opposing effects of FTO knockdown
on AMPk phosphorylation may lead to the decrease in glucose
uptake demonstrated in 3T3-L1 and SH-SY5Y cells as seen in
Figure 2 and 3. However, the role of AMPk in decreased glucose
uptake seen in FTO deficient cells is not clear and requires further
experimentation. Additionally, GLUT1, the primary glucose
transporter of basal glucose uptake in SH-SY5Y cells [15,30], is
allosterically inhibited by ATP [31], suggesting that increased ATP
levels in FTO-deficient SH-SY5Y cells may also potentially
contribute to decreased glucose intake. While the mechanism of
decreased glucose uptake in response to FTO knockdown is yet to
be determined, these results may provide insight into the
correlation between FTO variants and altered glucose metabolism
demonstrated in previous studies [9,12,27].
At present energy intake is the only obesity-associated trait
significantly and repeatedly associated with FTO variants
[3,11,19,20,21] in humans. Energy intake is tightly linked to
hypothalamic energy balance [32,33] and is mediated to a
significant extent through NPY [14,22], an orexigenic neuropep-
tide associated with increased energy intake in fasted mice [16].
We show in this study that FTO downregulation in SH-SY5Y
neuronal cells leads to a significant decrease in NPY expression
(Fig 4). The observed decrease in NPY mRNA may be modulated
by both a decrease in pAMPk [16], previously shown to activate
NPY neurons through Ca
2+ influx [34], and an observed increase
in pSTAT3 [14,22] (Fig 4). While POMC is also modulated by
AMPk and STAT3 [23], we observed no significant change in
POMC mRNA levels. This data is supported by a decrease in
NPY expression observed in FTO knockout mice [7] and an
increase in NPY expression observed in FTO knock-in mice [5],
and it provides a possible link between modulations in FTO
expression and alterations in neuropeptides involved in energy
intake.
The conclusions drawn in this study are based upon in vitro
experiments performed on immortalized cells and thus, their
Figure 3. Effect of FTO knockdown on glucose uptake and downstream signaling in 3T3-L1 cells. (A) Cells were transfected with siRNA
and then incubated 48 hrs post-transfection or differentiated for one week. Cells were then exposed to 80 mM 2-NBDG in DMEM media lacking
glucose and sodium pyruvate for 5 minutes and glucose-associated fluorescence was measured. Glucose uptake was decreased in both naı ¨ve (222%,
p=0.017) and differentiated (230%, p=0.0002) 3T3-L1 adipocytes. Y-axis represents Arbitrary Fluorescent Units (6SEM) from two independent
experiments run in quintuplicate and analyzed by one-way ANOVA with post-hoc analysis. (B) FTO knockdown decreases AMPk activation. 3T3-L1
cells were transfected with siRNA and then incubated 48 hrs post-transfection or differentiated for one week and subsequently immunoblotted.
pAMPk (Thr
172) was increased in both naı ¨ve (204.4%) and differentiated cells (37.8%) while total AMPk was unchanged. (C) FTO knockdown increases
Akt phosphorylation. pAkt (Ser
473) was increased in both naı ¨ve (69.9%) and differentiated cells (24.9%) while total Akt was unchanged. Blots and
densitometry data from a representative of two similar independent experiments.
doi:10.1371/journal.pone.0038444.g003
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tive. We encourage further research to confirm a connection
between FTO expression and energy intake. However, it is
interesting to note that our findings largely support previous
findings in which non-functional FTO mutations resulted in
decreased food intake and decreased accumulation of fat mass [6],
and FTO overexpression resulted in increase in fat accumulation
and energy intake in mice [5]. However, Tung et al. demonstrate
decreased energy intake in response to stereotactic hypothalamic
overexpression of FTO in rats, in stark contrast to the data
presented here and demonstrated earlier by others [35]. These
results, although very preliminary, coupled with previous findings
that attribute variants in the FTO gene to increased food intake
[3,19] and increased FTO mRNA translation [36] suggest that
alterations in the transcriptional status in FTO may contribute to
obesity by disrupting neuronal cellular energy status, and altering
the signaling mechanisms that are responsible for controlling
energy intake.
While previous studies by Tung et al on FTO have evaluated
the effect of modulation of FTO gene expression in the
hypothalamus [35] and other tissues [5,6,7], no study has
attempted to study the effect of alterations in FTO gene expression
in hypothalamic neurons or visceral adipocytes in relation to
cellular energy balance and downstream signaling cascades. This
study was performed in SH-SY5Y neuroblastoma cells and 3T3-
L1 adipocytes, cellular models chosen for their convenience and
ability to replicate some characteristics of neurons [37] and
adipocytes [38] in vivo. Data for both naı ¨ve and differentiated SH-
SY5Y neuronal cells and 3T3-L1 adipocytes are presented in this
paper since previous results suggest that FTO expression may
influence differentiation [39] or FTO inactivity may cause
premature senescence or decreased cell survival [25]. Thus, we
wanted to determine if differentiation modulated the effect of FTO
knockdown on metabolic parameters. In all experiments differen-
tiated cells performed in a similar manner as naı ¨ve cells, suggesting
a lack of impact of differentiation on FTO knockdown mediated
alterations in cellular metabolic activities. However, these results
are very preliminary and further experiments must be performed
that include knockdown and overexpression of FTO mRNA in
hypothalamic neurons and visceral adipocytes with corresponding
analysis of cellular energy balance and evaluation of the expression
of the proteins modulated in this study.
In summary, this study evaluated the effects of siRNA mediated
FTO knockdown on ATP levels and downstream signaling in
neuronal and adipocyte cell culture. We are the first to show that
alterations in FTO gene expression disrupt cellular energy balance
in a cell-type specific manner. Additionally, this study is the first to
identify the effects of FTO knockdown on AMPk phosphorylation,
and we suggest that AMPk may be a primary mediator of FTO’s
influence on energy intake and obesity. These findings provide
insight into FTO mediated obesity and support the notion that
FTO expression is an important driver of the development of
obesity.
Materials and Methods
Materials
SH-SY5Y neuroblastoma were acquired from American Type
Culture Collection (ATCC, Manassas, VA, CRL-2266) and 3T3-
L1 adipocytes were obtained from Elizaveta Benevolenskaya
(Department of Biochemistry and Molecular Genetics, University
of Illinois at Chicago) and cultured according to the specifications
described below. DMEM/F12 (1:1) (Cat No:11320-033), high-
glucose DMEM (Cat No:11965-092), Opti-MEM (Cat No:11058-
021), glucose-free DMEM (Cat No:11966-025), 1006 penicillin/
streptomycin solution (Cat No: 15070-063), 0.05% Trypsin/
EDTA (Cat No 25300-120), Molecular grade water(Cat No:
10977-015), HBSS (Cat No: 14025-092), PBS (Cat No: 20012-
050), and 2-[N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl) amino]-2-de-
oxy-d-glucose (2-NBDG) (Cat No: N13195) were purchased from
Figure 4. NPY expression in FTO deficient SH-SY5Y cells. (A) Cells were transfected with siRNA and then incubated 48 hrs post-transfection or
differentiated for 1 week. NPY mRNA levels were then analyzed and were decreased in both naı ¨ve (241%) and differentiated cells (221%). The Y-axis
represents percent of control (6Standard Deviation) of a representative experiment. (B) STAT3 activation is decreased in response to FTO
knockdown. SH-SY5Y cells were transfected with siRNA and then incubated 48 hrs post-transfection or differentiated for 1 week and subsequently
immunoblotted. pSTAT3 (Ser
727) was increased in differentiated cells (117.5%).
doi:10.1371/journal.pone.0038444.g004
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Calf sera (Cat No: S11450) were purchased from Atlanta
Biologicals (Lawrenceville, GA). Retinoic acid (Cat No: R2625),
Oligomycin A (Cat No: 7531), Dexamethasone (Cat No: D4902),
3-isobutyl-1-methylxanthine (IBMX) (Cat No: I5879) and insulin
(Cat No: I0516) were purchased from Sigma (St. Louis, MO).
The following reagents were used for immunoblotting; phos-
pho-protein extraction buffer (Boston Bioproducts, Ashland, MA,
Cat No: BP-116P); nitrocellulose membranes (Cat No: 162-0112),
from BioRad (Hercules, CA); and Pierce ECL western blot
substrate from Fisher Scientific (Rockford, IL, Cat No: 34075);
and protease inhibitor cocktail from Roche (Indianapolis, IN, Cat
No: 04-693-124-001).
Antibodies utilized in this study include Rabbit anti-STAT3
(pSer727, Cat No: 9134), STAT3 (Cat No: 9132), Akt (pSer473,
Cat No: 4721), Akt (Cat No: 9272), AMPk (pThr172, Cat No:
2531), and AMPk (Cat No: 2532) purchased from Cell Signaling
(Danvers, MA). Mouse anti-b-Actin (Cat No: 5441) antibody was
purchased from Sigma, and Sheep anti-Mouse IgG (Cat No:
NA931V) and Donkey anti-Rabbit IgG (Cat No: NA934V) were
purchased from GE healthcare, Piscataway, NJ.
Cell Culture and Differentiation
SH-SY5Y cells were maintained in DMEM/F12 (1:1) media,
supplemented with 10% (v/v) Fetal Bovine Serum and 1% (v/v)
Pen/Strep. SH-SY5Y cells were differentiated in DMEM/F12
media containing 10 mM retinoic acid for 7 days and given fresh
DMEM/F12 media with 10 mM retinoic acid every 48 hours.
Preadipocytes (3T3-L1 cells) were maintained in high glucose-
DMEM supplemented with 10% (v/v) Calf Serum and 1% (v/v)
pen/strep. 3T3-L1 cells were differentiated for three days in
differentiation media DMEM with 10% (v/v) FBS, containing
1 mg/ml insulin, 1 mM Dexamethasone, and 0.5 mM IBMX and
further matured for four days in DMEM media containing
10%(v/v) FBS and 1 mg/ml insulin.
Cells were maintained in 25 cm2 flasks at 37uC and 7% CO2 to
approximately 95% confluency and subsequently passaged with
0.05% Trypsin/EDTA.
Knockdown of FTO Expression Utilizing Small-Interfering
RNAs
3T3-L1 and SH-SY5Y cells were transfected with either anti-
FTO-siRNA purchased from Dharmacon (Lafayette, CO, Cat No:
D-004159-02) or Signal Silence Control siRNA (Cat No: 6568S,
Cell Signaling Technology), that does not lead to the specific
degradation of any cellular message, using either DharmaFECT 3
(3T3-L1) or DharmaFECT 2 (SH-SY5Y) transfection reagent,
respectively, according to the manufacturers specifications. Briefly,
cells were plated at appropriate cell concentrations (indicated in
specific experiments), and after 24 hours, plated cells were rinsed
26 with Opti-MEM media and pre-incubated for 30 minutes in
Opti-MEM media at 37uC and 7% CO2. A complex of 100 nM
siRNA and DharmaFECT transfection reagent in Opti-MEM was
then added, and cells were incubated for 24 hours in transfection
media. After 24 hours, the transfection media was removed, cells
were washed 16and incubated for 24 hours with the appropriate
media as described earlier. After a total of 48 hours from the start
of transfection, naı ¨ve cells were used for experimentation or
differentiation. 48 hours was selected since maximum downreg-
ulation of FTO occurred at this point. To achieve stable
transfection of siRNA during cellular differentiation, cells were
transfected for 48 hours as described above and subsequently
exposed to the differentiating agents as described in the previous
section. qRT-PCR was used to confirm FTO knockdown using
Anti-GAPD siRNA (Dharmacon D-001140-01) as a positive
control.
qRT-PCR
To analyze mRNA expression of FTO, NPY and POMC; 3T3-
L1 and SH-SY5Y cells were plated at 2610
4 or 3610
5 respectively
in 35 mm petri dishes and transfected with siRNA as described
previously. After 24 hours, dishes were washed 16with media and
replaced with appropriate media. After an additional 24 hours (48
hours after the start of transfection) or after differentiation, cells
were rinsed 26 with ice-cold PBS and total RNA was isolated
from siRNA treated cells using the PureLink Micro-to-Midi
TM
Total RNA Purification System from Invitrogen (Cat No: 12183-
018). cDNA synthesis and qPCR was performed using the Two-
Step qRT-PCR Kit from Invitrogen (Cat No: 11748-100), as
prescribed by the manufacturer and using the Applied Biosciences
7300 Real-Time PCR System. Primers used were obtained from
Integrated DNA Technologies (Coralville, Iowa) and the sequence
was as follows: FTO forward: 59 GAA TTC TAT CAG CAG
TGG CAG CTG 39, FTO reverse; 59 AGC CAT GCT TGT
GCA GTG TG 39, GAPDH forward: 59 TTG CCA ATG ACC
CCT TCA 39, GAPD reverse: 59 CGC CCC ACT TGA TTT
TGG A 39, NPY forward: 59 TCC AGC CCA GAG ACA CTG
ATT 39, NPY reverse: 59 AGG GTC TTC AAG CCG AGT
TCT39, POMC forward: 59 AGC CCG CCC AAG GAC AAG
39, POMC reverse: 59 TGC CCT CAC TCG CCC TTC T 39.
Immunoblotting
To determine the effect of FTO knockdown on expression levels
of involved proteins, SH-SY5Y and 3T3-L1 cells were plated at
3610
5 or 2610
4 cells per 35 mm petri dish, respectively, and
transfected with siRNA as described previously. After 24 hours,
dishes were washed 16with media and replaced with appropriate
media. After an additional 24 hours (48 total hours of transfection)
or after differentiation, cells were rinsed 26with ice-cold PBS, and
lysed in phospho-protein extraction buffer with protease inhibitor
cocktail (Roche) as described previously [40]. Cell lysates were
separated by 7.5% or 10% SDS-PAGE under reducing conditions.
Proteins were transferred to a nitrocellulose immobilization
membrane and immunoblotted using the enhanced ECL.
Determination of Cell Viability
To determine the effect of oligomycin and FTO siRNA on the
survival of 3T3-L1 adipocytes and SH-SY5Y neurons, cells were
plated at 50,000 cells or 200,000 cells per well, respectively, in 12
well plates in DMEM and appropriate media, as described above.
After 24 hours, cells were transfected with either FTO or Control
siRNA as described above for 48 hours. Cells were then treated in
the presence and absence of 10 mM oligomycin for 30 minutes
after which cells were trypsinized and counted with trypan blue
exclusion. Each data point was repeated in quadruplicate.
ATP Assay
To determine if changes in FTO expression modulate energy
balance in SH-SY5Y and 3T3-L1 cells, we quantified the levels of
ATP present within cells with or without FTO downregulation.
ATP content of cells was measured using the Perkin Elmer
ATPlite luminescence assay system (Waltham, MA, Cat No:
6016941). Briefly, SH-SY5Y and 3T3-L1 cells were plated at
2610
3 and 3610
3 cells/well, respectively, in a 96 well plate, and
transfected as described previously. After 24 hours, wells were
washed 16 with media and replaced with appropriate media.
After an additional 24 hours (48 total hours of transfection) or after
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incubated for 30 minutes in glucose-free media with or without
10 mM oligomycin, a specific inhibitor of ATP synthase to reduce
levels of endogenous ATP. Cells were then lysed with the provided
16mammalian cell lysis buffer for 5 minutes on an orbital shaker.
After which the provided reconstituted luciferase substrate was
then added to the cell lysate and incubated for 5 minutes. The
plates were then incubated in dark for 10 minutes, and
luminescence was measured using the Bio Tek Synergy 2 multi-
mode microplate reader (Winooski, TN).
Glucose Uptake Assay
2-[N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl) amino]-2-deoxy-d-glu-
cose (2-NBDG) (Invitrogen, Cat No: N13195), a non-hydrolysable
fluorescent glucose analog with a excitation/emission maxima of
,465/540 nm [41], was used to measure basal uptake of glucose
into SH-SY5Y cells. Briefly, SH-SY5Y and 3T3-L1 cells were
plated at 36103 and 26103 cells/well, respectively, in a 96 well
plate, and transfected as described previously. After 24 hours, wells
were washed 16in media and replaced with appropriate media.
After another 24 hours (48 total hours of transfection) or after
differentiation, cells were washed 16with DMEM media lacking
glucose and/or sodium pyruvate (Invitrogen, Cat No: 11966-025)
and exposed to 80 mM 2-NBDG for 5 minutes in glucose-free
DMEM media. 2-NBDG containing glucose-free DMEM was
then removed and cells were washed 26with ice-cold HBSS with
Ca2+ and Mg2+ (Invitrogen, Cat No: 14025-092) to remove
residual 2-NBDG. Cell-associated fluorescent signal was analyzed
using the Bio Tek Synergy 2 multi-mode microplate reader.
Analysis of Results
qPCR results were analyzed by the Applied Biosciences 7300
Real-Time PCR System software with GAPD mRNA serving as a
positive internal control. Immunoblotting results were analyzed by
densitometric analysis using the Image J software from the
National Institutes of Health with values representing percent of
control from an average of triplicate experiments. Experiments on
cell viability were analyzed using repeated measures ANOVA with
a=0.05. ATP and Glucose experiments were performed in with
paired control groups in ‘‘N’’ number of replicates as indicated,
respectively, and analyzed against the appropriate control siRNA
and diluent groups using a one-way ANOVA with post-hoc
analysis. Data is presented as FTO siRNA vs Control siRNA,
because diluent groups were found be uniformly similar to Control
siRNA groups. Significance was established at a=0.05.
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